Published in Rev Urol on January 01, 2010
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol (1987) 3.06
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol (2006) 2.04
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02
Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol (2001) 1.91
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol (2005) 1.82
Regulation of immune responses by T cells. N Engl J Med (2006) 1.76
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res (1999) 1.45
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest (1997) 1.40
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med (2005) 1.31
Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother (2005) 1.00
Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res (2007) 0.98
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother (2000) 0.96
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother (2005) 0.92
Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol (2005) 0.85
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol (2006) 2.04
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol (2004) 1.87
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Paths of FGFR-driven tumorigenesis. Cell Cycle (2009) 1.63
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol (2002) 1.61
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol (2004) 1.55
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer (2006) 1.54
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int (2012) 1.51
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2012) 1.47
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res (2004) 1.45
Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology (2005) 1.43
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol (2006) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Clin Cancer Res (2008) 1.39
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
Fully automated, quantitative, noninvasive assessment of collagen fiber content and organization in thick collagen gels. J Appl Phys (2009) 1.32
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med (2005) 1.31
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer (2013) 1.28
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer (2012) 1.22
Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol (2002) 1.21
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res (2003) 1.18
Anomalies of the wolffian duct derivatives encountered at radical prostatectomy. Rev Urol (2005) 1.18
Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol (2004) 1.17
T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther (2010) 1.17
Optimal management of metastatic renal cell carcinoma: current status. Drugs (2013) 1.17
Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell (2012) 1.16
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Endogenous optical biomarkers of normal and human papillomavirus immortalized epithelial cells. Int J Cancer (2008) 1.16
Activation of initiator caspases through a stable dimeric intermediate. J Biol Chem (2002) 1.09
Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res (2003) 1.07
Radiation therapy after radical prostatectomy: why patience is a virtue! The case for salvage radiation therapy. Rev Urol (2002) 1.07
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol (2004) 1.07
Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol (2004) 1.07
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol (2013) 1.07
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood (2011) 1.07
Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol (2011) 1.06
An inducible system for the study of FGF signalling in early amphibian development. Dev Biol (2003) 1.05
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer (2013) 1.05
Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer (2012) 1.04
Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res (2003) 1.02
Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res (2003) 1.02
Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol (2009) 1.02
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate (2009) 1.02
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol (2012) 1.00
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int (2012) 1.00
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol (2005) 0.99
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol (2002) 0.99
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol (2004) 0.99
Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res (2007) 0.98
Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res (2007) 0.98
Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology (2004) 0.98
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol (2012) 0.98
Wnt and Notch pathways have interrelated opposing roles on prostate progenitor cell proliferation and differentiation. Stem Cells (2011) 0.97
Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate (2005) 0.97
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.96
Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. Eur Urol (2012) 0.96
Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol (2012) 0.96
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95
Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One (2012) 0.95
Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol (2004) 0.95
Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques. Stem Cells (2015) 0.94
Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res (2008) 0.94
A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest (2011) 0.94
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs (2009) 0.93
The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol (2011) 0.93